# A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

> **NCT05604560** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Lei Zheng** · enrollment: 25 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** SX-682

## Key facts

- **NCT ID:** NCT05604560
- **Lead sponsor:** Lei Zheng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-08
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-07-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05604560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05604560, "A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05604560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*